You are here: Industry Insights > acquisition

News List

Abbott to acquire Cephea Valve Technologies, Inc. pharma
January 17, 2019
Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease.
What Are the Most Important Acquisitions in 2018? en-cphi.cn
January 16, 2019
What Are the Most Important Acquisition in 2018?
AGC to Acquire Malgrat Pharma Chemicals americanpharmaceuticalreview
January 16, 2019
AGC has entered into an agreement with Boehringer Ingelheim to acquire its subsidiary Malgrat Pharma Chemicals, S.L.U. (MPC). Located in Spain, MPC manufactures synthetic pharmaceutical active ingredients used for ....
ProKidney Announces $62 Million Acquisition of inRegen americanpharmaceuticalreview
January 15, 2019
ProKidney announces the acquisition of inRegen and its affiliate, Twin City Bio. ProKidney was founded by a group of investors led by Pablo Legorreta, the Founder and CEO of Royalty Pharma.....
Eli Lilly to buy Loxo Oncology for $8 billion expressbpd
January 10, 2019
The deal follows Bristol-Myers Squibb Co agreement last week to buy Celgene Corp for $74 billion, and gives Lilly access to Loxo’s portfolio of targeted medicines that treat cancers caused by rare gene mutations
Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc. pharmafocusasia
January 10, 2019
Generex Biotechnology Corporation is pleased to announce that the company has completed the acquisition of 51% of Olaregen Therapeutix Inc....
Takeda unlikely to sell OTC unit to pay Shire merger debts pharmaphorum
January 08, 2019
Takeda’s $59 billion takeover of Shire is due to close tomorrow (Tuesday) and the company’s CEO Christophe Weber has already given some strong clues about the company’s strategy once the deal completes.
Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyout fiercepharma
January 08, 2019
On the first day of biopharma’s largest confab, the J.P. Morgan Healthcare Conference, Eli Lilly confirmed that big-ticket M&A is back in fashion in the industry.
Post-Monsanto Era of Bayer Group: To Lay off 10,000+ Employees, Scale Back Business, and Develop Life Science PharmaSources/Youyi
January 08, 2019
Bayer formally acquired the U.S. agricultural company: Monsanto for a price of USD63 billion on June 7, 2018 upon approval of the relevant U.S. and European regulators.
Lilly Announces Agreement to Acquire Loxo Oncology americanpharmaceuticalreview
January 08, 2019
Eli Lilly and Company and Loxo Oncology announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion ......

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page